Amarin Corp. (AMRN) Misses Q4 EPS by 3c, Sales Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Amarin Corp. (AMRN) Misses Q4 EPS by 3c, Sales Beat

Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations

February 28, 2017 6:00 AM EST

$130.1 Million and $38.7 Million Total Revenue for Full Year and Fourth Quarter 2016 Reflect Increases of 59% and 45% Compared to Corresponding Periods in 2015

 REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Reach Onset of Final Target Event Near the End of 2017

Management to Host Conference Call at 7:30 a.m. ET Today

BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial... More